Investment Rating - The report does not explicitly provide an investment rating for the industry. Core Insights - The report highlights significant advancements in the pharmaceutical industry, particularly in the development and approval of innovative drugs, with a focus on oncology and immunotherapy [5][6][10]. Summary by Sections 1. Latest Policy Updates - The National Medical Products Administration (NMPA) has issued several key announcements, including guidelines to strengthen the supervision of entrusted drug production and the release of the 2025 Clinical Application Guidelines for Antitumor Drugs [10][15][18]. - New regulations aim to support the development of innovative drugs and ensure the quality and safety of pharmaceuticals through enhanced management practices [11][12][14]. 2. Domestic New Drug Approvals - In January 2026, a total of 172 new drugs were approved for clinical trials, a decrease of 55 from the previous month. Among these, 78 were chemical drugs, 88 were biological products, and 6 were traditional Chinese medicines [22][23]. - The majority of new drug approvals were in the fields of oncology and immune modulation, accounting for 53% of the total [22]. 3. Global Innovative Drug Development - The report lists several drugs that have shown positive clinical results, including Neumora Therapeutics' NMRA-511 and GSK's new hepatitis B drug, which achieved success in phase 3 studies [6][10]. - Notable approvals include the BCL-2 inhibitor from BeiGene, which received dual indications for chronic lymphocytic leukemia and mantle cell lymphoma [40][41]. 4. New Drug Listings - The report details new drug listings, including the approval of the combination drug for ADHD treatment by Aikobai, which has shown significant efficacy in clinical trials [41][43]. - The approval of Merck's drug for pulmonary arterial hypertension represents a new treatment option that addresses the underlying causes of the disease rather than just symptomatic relief [40].

Investment Rating - The report does not explicitly provide an investment rating for Innovent Biologics [4]. Core Insights - Innovent Biologics announced a milestone deal with Eli Lilly on February 8, 2026, granting overseas rights to certain oncology and immunology pipeline assets, receiving an upfront payment of $350 million and potential milestone payments of up to $8.5 billion [4][5]. - This transaction is viewed positively, reinforcing the recognition of Innovent's R&D capabilities by global pharmaceutical companies, which is a significant differentiator in the Chinese biotech sector [6]. - The company is expected to release at least nine Phase I/II data assets in oncology, cardiovascular/metabolic diseases, and autoimmune diseases between 2026 and early 2027, which could unlock substantial option value [6]. Summary by Sections Company Overview - Innovent Biologics is a China-based biopharmaceutical company with a global perspective, focusing on the comprehensive development and commercialization of innovative drugs [10]. Recent Developments - The deal with Eli Lilly involves early development led by Innovent from proof of concept to Phase II, after which Eli Lilly will handle late-stage development and commercialization outside China [5]. - The assets involved in this transaction are undisclosed clinical projects, and the number of projects is fewer than the 11 preclinical assets involved in a previous deal between Hengrui Medicine and GSK [5]. Financial Performance - Innovent's product sales for Q4 2025 reached 3.3 billion yuan, representing a year-on-year growth of over 60%, exceeding market consensus expectations [6]. Catalysts - Key catalysts for 2026 include updates on proof of concept data for IBI363 in frontline non-small cell lung cancer and the initiation of multiple global Phase III projects led by Takeda [7].

Core Viewpoint - The company, Jiangsu Hengrui Medicine Co., Ltd., has received acceptance for its drug application for SHR-A1811 (注射用瑞康曲妥珠单抗) from the National Medical Products Administration, which has been included in the priority review process [1] Group 1: Drug Application and Clinical Trials - The drug application is based on a randomized, open-label, positive-controlled, multi-center Phase III clinical trial [1] - The trial aims to evaluate the efficacy and safety of SHR-A1811 compared to standard treatment in HER2-positive advanced colorectal cancer patients who have failed previous treatments with oxaliplatin, fluorouracil, and irinotecan [1] - The study is led by Dr. Li Jin from Shanghai Gaobo Cancer Hospital and Professor Yuan Ying from the Second Affiliated Hospital of Zhejiang University School of Medicine, with participation from 40 centers nationwide [1] Group 2: Study Outcomes - The primary endpoint of the study is progression-free survival (PFS) assessed by an independent imaging review committee (IRC) according to RECIST v1.1 [1] - Results indicate that SHR-A1811 significantly extends PFS in HER2-positive advanced colorectal cancer patients compared to standard treatment, reducing the risk of disease progression or death [1] - Overall survival (OS) data shows a trend of benefit, although it is currently only observed [1]

Core Viewpoint - The company, Jiangsu Hengrui Medicine Co., Ltd., has received a notice from the National Medical Products Administration (NMPA) regarding the acceptance of its drug application for injection of Rukang Trastuzumab, which is now included in the priority review process [1] Group 1 - The drug name is Rukang Trastuzumab for injection [1] - The dosage form is an injection [1] - The acceptance number for the application is CXSS2600018 [1] Group 2 - The application is currently in the listing phase [1] - The applicant for the drug is Suzhou Merdia Biopharmaceutical Co., Ltd., a subsidiary of the company [1] - The proposed indication is for the treatment of adult patients with HER2-positive colorectal cancer who have failed treatment with oxaliplatin, fluorouracil, and irinotecan [1]

本次新适应症申报是基于一项随机、开放、阳性药物对照、多中心设计的Ⅲ 期临床试验，该研究旨在 评估瑞康曲妥珠单抗(SHR-A1811)对比标准治疗方案在经奥沙利铂、氟尿嘧啶类和伊立替康治疗失败的 HER2阳性晚期结直肠癌受试者中的有效性和安全性，并探索该药物的免疫原性及药代动力学特征。本 研究由上海高博肿瘤医院李进院长和浙江大学医学院附属第二医院袁瑛教授共同担任主要研究者，全国 40家中心共同参与。主要终点为独立影像评审委员会(IRC)依据RECIST v1.1 评估的无进展生存期 (PFS)。研究结果显示，与标准治疗方案相比，瑞康曲妥珠单抗能显著延长HER2 阳性晚期结直肠癌患 者的PFS，降低疾病进展或死亡风险。总生存期(OS)数据目前观察到获益趋势。 智通财经APP讯，恒瑞医药(01276)发布公告，近日，江苏恒瑞医药股份有限公司(以下简称"公司")子公 司苏州盛迪亚生物医药有限公司收到国家药品监督管理局(以下简称"国家药监局")下发的《受理通知 书》，公司注射用瑞康曲妥珠单抗的药品上市许可申请获受理，且已被纳入优先审评程序。 ...

恒瑞医药公告要点解读 核心事项 恒瑞医药子公司苏州盛迪亚的注射用瑞康曲妥珠单抗新适应症上市申请获国家药监局受理，并纳入优先 审评程序。 国内尚无HER2靶向药获批用于HER2阳性结直肠癌，存在未满足临床需求 关键信息 同类产品2024年全球销售额合计约65.57亿美元 新适应症：治疗经奥沙利铂、氟尿嘧啶和伊立替康治疗失败的HER2阳性结直肠癌成人患者 该项目累计研发投入约17.73亿元（未经审计） 已获批适应症：2025年5月已获批用于HER2激活突变的晚期非小细胞肺癌 临床数据：基于III期临床试验，结果显示较标准治疗方案显著延长PFS，降低疾病进展或死亡风险 市场情况： ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-024 江苏恒瑞医药股份有限公司 关于药品上市许可申请获受理并纳入优先审评程序 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公 ...

来源：智通财经网 2月10日，港交所(00388)发布2025年香港股权资本市场回顾。2025年，香港资本市场表现亮眼，许多上 市股份表现优秀、成交一再创新高，港股通交投活跃。根据Dealogic的数据，2025年香港股权资本市场 的集资额达1,030亿美元，同比升164%。其中，首次公开招股集资规模达374亿美元，同比增长231%； 上市后再融资规模达660亿美元，同比升136%。与此同时，二级市场亦相当活跃：现货市场平均每日成 交额同比升89.5%，港股通亦非常活跃。 两大增长动能 香港资本市场助力各不同发展阶段的发行人实现融资，年内新股发行及再融资活动均大幅增长。 2025年底，香港重登全球新股集资中心榜首，119家新上市公司集资共374亿美元，当中包括全球五大新 股的其中两只。全年集资总额更是香港2021年以来的新高，超过前三年总和。 根据Dealogic及彭博的数据，新股上市后表现强劲，集资额1亿美元或以上的新股，上市首日股价平均 上升23.8%，上市后一个月平均涨幅达30.7%，是近20年来的最佳成绩。 数据亦显示，香港上市后再融资额增至660亿美元，创下2021年以来的最高纪录。其中200亿美元 ...

数据亦显示，香港上市后再融资额增至660亿美元，创下2021年以来的最高纪录。其中200亿美元是发行人通过发行股票挂钩产品获得 的融资，融资额同创新高。 年内亦录得多宗标志性交易，逾10亿美元大型交易20宗，包括全球汽车行业规模最大的配售交易及全球第二大科技类可转换债券交 易。 2月10日，港交所(00388)发布2025年香港股权资本市场回顾。2025年，香港资本市场表现亮眼，许多上市股份表现优秀、成交一再创新 高，港股通交投活跃。根据Dealogic的数据，2025年香港股权资本市场的集资额达1,030亿美元，同比升164%。其中，首次公开招股集 资规模达374亿美元，同比增长231%；上市后再融资规模达660亿美元，同比升136%。与此同时，二级市场亦相当活跃：现货市场平均 每日成交额同比升89.5%，港股通亦非常活跃。 两大增长动能 香港资本市场助力各不同发展阶段的发行人实现融资，年内新股发行及再融资活动均大幅增长。 2025年底，香港重登全球新股集资中心榜首，119家新上市公司集资共374亿美元，当中包括全球五大新股的其中两只。全年集资总额 更是香港2021年以来的新高，超过前三年总和。 根据Dea ...

Core Insights - Hong Kong's capital market showed remarkable performance in 2025, with total fundraising reaching $103 billion, a year-on-year increase of 164% [1][3] - The initial public offering (IPO) fundraising amounted to $37.4 billion, up 231% year-on-year, while post-listing refinancing reached $66 billion, a 136% increase [1][3] Group 1: Market Performance - Hong Kong regained its position as the global leader in new stock fundraising by the end of 2025, with 119 new listings raising a total of $37.4 billion, surpassing the total from the previous three years [3] - The average daily trading volume in the secondary market increased by 89.5% year-on-year, indicating high trading activity [1] Group 2: New Listings and Performance - New stocks with fundraising of $100 million or more saw an average first-day price increase of 23.8%, with an average one-month increase of 30.7%, marking the best performance in nearly 20 years [5] - Notable transactions included 20 large deals exceeding $1 billion, including the largest placement in the global automotive sector and the second-largest convertible bond deal in the tech sector [5] Group 3: Investor Participation - The investor base in Hong Kong's primary and secondary markets has become increasingly diverse, including global institutional investors and retail investors from mainland China [9] - Institutional investors accounted for a significant portion of the top 20 most active cornerstone investors in Hong Kong's equity capital market [9] Group 4: Industry Diversity - Hong Kong maintained its status as a diversified fundraising center, ranking among the top globally in various industry fundraising scales [11] - In the industrial and new energy sectors, Hong Kong ranked first globally in new stock fundraising at $14.3 billion and second in equity capital market issuance at $24.7 billion [13] Group 5: Future Trends - The capital market in Hong Kong started strong in 2026, with equity capital market issuance reaching $15.8 billion by January 30, six times the amount from the same period in 2025 [16] - The artificial intelligence sector is expected to play a significant role in IPO activities, contributing to a vibrant ecosystem for innovative companies [16]